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Abstract
Treponema pallidum subspecies pallidum (Tp) is the causative agent of syphilis which mainly spreads through sexual
contact, blood transfusion and perinatal route. In order to curtail the spread of the infection and to clinically manage the
disease, timely, accurate and reliable diagnosis is very important. We have developed an immunoassay for the detection of
treponemal antibodies in human serum or plasma samples. In vivo biotinylated and non-biotinylated versions of the
recombinant antigen were designed by the fusion of three Tp-specific antigens namely Tp15, Tp17 and Tp47. These fusion
antigens were expressed in E. coli and purified using single-step metal affinity chromatography. Biotinylated fusion antigen
immobilized on streptavidin coated plate was used to capture the treponemal antibodies and the non-biotinylated antigen
coated on europium nanoparticles was used as tracer. Assays with two different incubation times of 10 min and 1 h were
developed, and following the incubation the europium fluorescence was measured using time-resolved fluorometry. The
developed time-resolved fluorometric (TRF) immunoassays were evaluated with in-house and commercial serum/plasma
sample panels. For well-established treponemal antibodies positive or negative samples, the sensitivity of TRF immunoassay
with 10 min incubation time was 97.4%, and of TRF immunoassay with 1 h incubation time was 98.7%, and the specificities
of both the TRF immunoassays were 99.2%. For the samples with discordant results with the reference assays, both the TRF
immunoassays showed better specificity than the Enzygnost syphilis enzyme immunoassay as a screening test. The two
different incubation times did not have any significant effect on the signal to cutoff (S/Co) ratios obtained with the two
immunoassays (p = 0.06). Our results indicate that the developed immunoassay with a short incubation time of 10 min has
the potential to be used in clinical laboratories and in blood-bank settings as a screening test for treponemal antibodies.
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Introduction
Treponema pallidum subspecies pallidum (Tp), a spirochete bacte-
rium, is responsible for syphilis which is a sexually transmitted
infection in humans. In 2008 there were an estimated 10.6 million
new cases of syphilis in adults worldwide [1]. Worldwide nearly 1.4
million pregnant women, with the disease burden of 44% in Asia
and 39% in Africa, had active syphilis infection and were at the
risk of transmitting the disease to their unborn babies [2]. Syphilis
infection is well known for its multiple stages of pathogenicity, split
by stages of latency. As the stages of infection proceed, so does the
complication of the disease, thus it is essential that the infection is
diagnosed and treated as early as possible [3–6]. Syphilis is also
one of the transfusion-transmissible infections, which is of a
particular concern for the developing countries. To curtail the
spread of syphilis through the transfusion of blood and blood-
products meticulous screening of the donated blood is paramount
[7–9].
Serological diagnosis of syphilis includes the detection of two
different kinds of molecules, namely treponemal and non-
treponemal antibodies. Treponemal antibodies are raised against
specific antigens of Tp, and non-treponemal antibodies are raised
against cardiolipin [10]. Treponemal antibodies last throughout
the life, whereas non-treponemal antibodies are present only in an
on-going infection, thus non-treponemal antibody tests are useful
to distinguish between convalescent cases and active infections.
However, non-treponemal antibody tests usually suffer from low
specificity, thus a combination of treponemal and non-treponemal
antibodies tests are required for the clinical diagnosis of syphilis.
According to WHO’s recommendation, in a blood-bank setting
screening of only treponemal antibodies should be performed in a
population with low incidence of syphilis [11]. Three Tp
membrane proteins Tp15, Tp17 and Tp47, named after their
respective sizes in kDa, are known to be highly immunogenic, and
varying titers of the (treponemal) antibodies against these proteins
can be detected in individuals during primary, secondary and
latent stages of syphilis infections [12–16]. We have developed a
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double antigen sandwich immunoassay for the detection of
treponemal antibodies using a recombinant fusion protein of
Tp15, Tp17 and Tp47, and europium nanoparticle. The
developed immunoassay is a third generation assay for the
detection of total treponemal antibodies (IgM and IgG) intended
to be used in clinical laboratories and in blood-bank settings as a
screening test. The developed immunoassay was evaluated using
in-house and commercial serum/plasma sample panels, and
manifested high degrees of sensitivity and specificity.
Materials and Methods
Ethics statement
All samples of the in-house human serum panel were collected
with informed consent from individuals who might have syphilis in
order to perform serologic tests as routine clinical practice. All of
these samples were coded samples and strict anonymity was
maintained throughout this study. According to the Finnish
Medical Research Act (No. 488/1999), Chapter 1, Sections 1, 2
and 3, the research of the present study is not medical research,
and thus, it was not necessary to obtain a separate approval from
the local Ethics Committee to use the samples in the syphilis
serology assays of the present study.
Generation of recombinant Tp antigens
The synthetic gene, codon-optimized for E. coli expression was
designed and custom-synthesized from Geneart (Regensburg,
Germany), and used to express two versions (biotinylated and
non-biotinylated) of the encoded recombinant (r-) Tp antigen. The
r-Tp antigen, henceforth termed as Tp15-17-47, was a designer
fusion antigen of three Tp membrane proteins namely, Tp15,
Tp17 and Tp47, respectively, with flexible tetra-glycyl (G4)
residues expressing in between the three proteins. This synthetic
gene was inserted into pET-32a(+) at BamHI/SalI restriction sites,
in-frame with the vector-encoded thioredoxin (Trx) gene and 6x-
His tag encoding sequence to express r-Trx-Tp15-17-47 (hence-
forth termed as r-Tp15-17-47), and into pTrx-BAP vector [17,18]
in-frame with the vector encoded Trx (thioredoxin)-6x-His tag-
BAP (biotin acceptor peptide) sequences at the amino terminus, to
express the r-Trx-BAP-Tp15-17-47 (henceforth termed as r-Bio-
Tp15-17-47) antigen. The resultant plasmids were transformed
separately into E. coli BL21(DE3) cells, and induced to express with
1 mM IPTG (isopropyl-b-d-thiogalactopyranoside; Qiagen, Hil-
den, Germany). In order to achieve biotinylation of the r-Bio-
Tp15-17-47 antigen in vivo, E. coli cells expressing this antigen were
co-transformed with IPTG-inducible biotin ligase expressing
plasmid pBirA [17] and cultured in medium supplemented with
biotin (10 mg/ml). After expression of the antigens at 16uC, they
were purified from induced cells under denaturing conditions.
Briefly, induced cell pellets from 1-L shake flask culture were re-
suspended in lysis buffer (20 mM Tris, 8 M Urea, 300 mM NaCl,
10 mM b-mercaptoethanol, 10% glycerol, 20 mM imidazole,
pH 8.0) and lysed by sonication at 4uC (Sonics Vibracell
sonicator). The resulting lysates were clarified by centrifugation
and chromatographed on 5 ml Ni-NTA super flow resin (Qiagen,
Hilden, Germany) columns. After washing the columns with the
lysis buffer, they were washed with wash buffer (20 mM Tris, 8 M
urea, 300 mM NaCl, 10 mM b-mercaptoethanol, 10% glycerol,
20 mM imidazole, 1% Tween-20, pH 8.0) and the elutions were
performed using linear gradients of imidazole (20–500 mM) in
wash buffer. All the eluted fractions were analyzed by SDS–
PAGE, the pure homogeneous fractions were pooled together, and
treated with 50 mM DTT and 10 mM EDTA at 37uC for 3 h,
and dialyzed extensively against 10 mM Tris, 100 mM NaH2PO4,
1 mM EDTA, pH 8, at 4uC. The dialyzed proteins were
centrifuged, glycerol was added to them up to a final concentration
of 10%, and the resulting proteins were concentrated to ,1 mg/
ml, filtered with 0.22 mm membrane and stored at 220uC, until
further use.
Preparation of recombinant Tp antigen coated on
europium nanoparticles
The Eu3+ chelate-doped Fluoro-MaxTM polystyrene nanopar-
ticles (Seradyn Inc., Indianapolis, IN) (107 nm in diameter, .30
000 chelates per particle) have been described before [19,20]. The
buffer of r-Tp15-17-47 was changed to 50 mM sodium carbonate
buffer, pH 9.6 using Nucleic Acid Purification (NAP) Sephadex G-
25 columns (GE Healthcare, Uppsala, Sweden). The coating of r-
Tp15-17-47 on Eu-nanoparticles was performed essentially as
described before [18]. r-Tp15-17-47 coated Eu-nanoparticles were
stored in 2 mM Tris-HCl, pH 9.0 supplemented with 0.1% BSA
and 0.01% sodium azide at 4uC, covered from light. Before every
use particles were vortexed thoroughly and sonicated to disperse
any large aggregates.
Serum/plasma samples and their characterization
A collection of 311 human serum/plasma samples was used in
this study. This consisted of one in-house panel and two
commercially procured panels. The in-house panel of 285 serum
samples–where some of the samples were follow-ups from the
same patient–was collected at Department of Medical Microbiol-
ogy and Immunology, University of Turku, Turku, and charac-
terized using the three reference assays i.e. Enzygnost Syphilis
competitive enzyme immunoassay (EIA) (Siemens Healthcare
Diagnostics Products GmbH, Marburg, Germany) and Treponema
pallidum haemagglutination assay (TPHA) (Cellognost-Syphilis H,
Siemens Healthcare Diagnostics Products GmbH) for the detec-
tion of treponemal antibodies, and Oxoid VDRL (Veneral disease
research laboratory) carbon antigen agglutination test (Oxoid,
Basingstoke, UK) for the detection of reagin (cardiolipin)
antibodies. Enzygnost syphilis EIA was used as primary screening
test; only the positive samples in this test were tested further with
TPHA and VDRL. Samples that appeared non-conclusive with
these three reference assays were tested further with Inno-Lia
Syphilis score line immunoassay (Innogenetics NV, Gent,
Belgium). The two commercial panels, Syphilis Mixed Titer
Performance Panel (PSS202) and Syphilis Qualification Panel
(QSS701) (SeraCare Life Sciences, Milford, MA, USA) were
characterized by the panel supplier using the commercially
available assay kits.
In-house TRF immunoassays for the screening of
treponemal antibodies
r-Bio-Tp15-17-47 antigen (200 ng/100 ml/well) was immobi-
lized on streptavidin-coated low-fluorescence microtiter wells
(Kaivogen Oy, Turku, Finland) in the assay buffer (50 mM
sodium carbonate, pH 9.6, 25 mM NaCl, 2.5% BSA, 1.25%
sucrose, 0.06% c-globulins from bovine blood, 0.1% Tween-20,
0.05% NaN3) by incubating it for 1 h at RT with shaking. The
wells were then washed twice with wash buffer (50 mM potassium
phosphate buffer, pH 7.2, 154 mM NaCl, 0.5 M KCl, 0.1%
Tween-20). The antigen-coated wells were used in two TRF
immunoassay formats with two different incubation times of
10 min and 1 h. For TRF immunoassay with 10 min incubation
time, 25 ml diluted serum/plasma sample (1:5 in assay buffer) was
added to each well, then 25 ml assay buffer containing 26108 Eu-
nanoparticles was added, and incubated for 10 min at RT with
Immunoassay for Treponemal Antibodies
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shaking. For TRF immunoassay with 1 h incubation time, after
adding diluted serum/plasma sample as above, 25 ml assay buffer
containing 56107 Eu-nanoparticles was added, and incubated for
1 h at RT with shaking. After the incubation, the wells were
washed 6 times with wash buffer. Time-resolved fluorescence for
europium was measured (lex: 340 nm; lem: 615 nm) from dry
wells using Victor3V 1420 Multilabel counter (modified standard
europium protocol; measurement height 5 mm).
Statistical analysis
Samples were designated as either positive or negative using
cutoff values of 1203 counts per second (cps) and 1212 cps,
respectively, for the TRF immunoassays with 10 min and 1 h
incubation times. These cutoff values were obtained by adding 4
times the standard deviation (SD) to the mean read-out of 119 Tp-
negative samples (all the samples of category #6, Table 1, except
one sample which was repeatedly positive with the TRF
immunoassays) of the in-house panel in the TRF immunoassays
with 10 min incubation (mean= 321 cps; SD=221 cps) and in
1 h incubation (mean= 308 cps; SD=226 cps) time as described
above. Serum samples with ‘signal-to-cutoff’ (S/Co) ratios of ,1.0
were designated as negative, while those with S/Co$1.0 were
designated as positive.
Statistical significance of differences in sensitivities between the
two TRF immunoassays was determined using two-tailed paired t-
test. Differences were considered to be of statistical significance
when the probability (p) was ,0.05.
Results
Design, expression and purification of the recombinant
antigens
The design of the r-Tp15-17-47 antigen and its in vivo
biotinylated version, r-Bio-Tp15-17-47 is shown in Figure 1A. r-
Tp15-17-47 antigen was genetically engineered to express as an in-
frame fusion with Trx and a 6x-His tag at its amino terminus to
facilitate its solubility and purification. The in vivo biotinylated
version also included BAP sequence. In order to efficiently in vivo
biotinylate the antigen, r-Bio-p15-17-47 was co-expressed with
biotin ligase enzyme in the media supplemented with biotin. Both
the antigens were produced starting from a 1-L shake-flask culture
of E. coli. The lysed cells were analysed before and after induction
by SDS-PAGE. Typical expression profiles of the clones are shown
in Figure 1B. The induced cell lysates harbouring the r-Tp15-17-
47-expressing plasmids did not clearly show the distinct over-
expression of a new polypeptide of the expected molecular weight
of ,95 kDa, which is the calculated size of r-Tp15-17-47. The
induced cells harbouring the r-Bio-Tp15-17-47-expressing plas-
mids showed the distinct bands of new polypeptides of ,97 and
,34 kDa, which were consistent with the calculated sizes of the r-
Bio-Tp15-17-47 and the biotin ligase enzyme, respectively. In
both the cases, the un-induced cells did not show the presence of
these proteins. Western blot analysis performed with the lysates
using a monoclonal antibody specific to the 6x-His tag confirmed
the presence of both r-Tp15-17-47 and r-Bio-Tp15-17-47 proteins
in their respective induced lysates. However, initial studies
revealed that in the native conditions both the proteins did not
bind to the Ni-NTA resin (data not shown). We speculated that
this was due to the inaccessibility of 6x-His tag to bind to the resin.
To circumvent this problem urea was used to make the 6x-His tag
accessible and the Ni-NTA affinity purifications of the antigens
were carried out under denaturing conditions. Purified proteins
were treated with DTT and EDTA, and dialyzed to remove the
denaturants, and soluble proteins were analysed by SDS-PAGE
(Figure 1B). At least 25 mg of each of the soluble purified proteins
were obtained from 1-L induced E. coli culture.
In-house TRF immunoassays for treponemal antibodies
After the purification of the pair of recombinant antigens, these
antigens were utilized for the development of double antigen
sandwich immunoassays for the detection of treponemal antibod-
ies (immunoglobulins). In these immunoassays, the treponemal
immunoglobulins (Ig) of both the classes (IgM and IgG classes)
from serum/plasma samples were captured on r-Bio-Tp15-17-47
antigens immobilized on streptavidin-coated microtiter wells. The
detection of these antibodies was made by r-Tp15-17-47 coated on
Eu-nanoparticles, and the fluorescence was measured using time-
resolved fluorometry. Two different incubation times and different
amount of tracers were used for the two TRF immunoassays;
however the design of the both the TRF immunoassays is
essentially the same, which is presented in Figure 2A.
The performances of both the TRF immunoassays were
evaluated with serum/plasma samples (n = 311) from an in-house
panel and two commercially available panels. The samples
(n = 285) of in-house panel were divided into six different
categories based on their reactivities with the three reference
assays (Table 1). Category #1 consisted of 56 samples that
belonged to 31 people, and the samples were (sero)positive with all
three reference assays. All of these samples were identified as
Table 1. Evaluation summary of the TRF immunoassays using the in-house serum sample panel.
Reference assaysa TRF immunoassaysa
Category #
No. of samples
(n =285) Enzygnost Syphilis TPHA VDRL/Oxoid 10 min incubation 1 h incubation
1 56 56/56 56/56 56/56 56/56 56/56
2 73 73/73 73/73 0/73 69/73 71/73
3 27 27/27 0/27 0/27 10/27 10/27
4 8 8 (+/2)/8 0/8 0/8 0/8 0/8
5 1 1/1 0/1 1/1 1/1 1/1
6 120 0/120 ND ND 1/120 1/120
aResults expressed as ‘number of positive samples with the indicated assays’/‘total number of samples’. ‘+/2’ indicates that indeterminate result was obtained with the
respective assay; ‘ND’ indicates that the test was not done.
doi:10.1371/journal.pone.0084050.t001
Immunoassay for Treponemal Antibodies
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e84050
positive in both the in-house TRF immunoassays, without any
ambiguity.
Category #2 (Table 1) consisted of 73 samples from 52 people.
All of these samples were positive with Enzygnost and TPHA, and
negative with VDRL. Out of these 73 samples, two were detected
as negative in both the TRF immunoassays, and two as negative in
only the TRF immunoassay with 10 min incubation time. The
latter two samples had S/Co ratios of 1.4 and 1.0 respectively in
Figure 1. Design, expression and purification of the r-antigens used in the study. (A) The r-Tp15-17-47 antigen is a chimeric in-frame fusion
construct containing thioredoxin, 6x His tag (indicated by the asterisk), followed by the membrane proteins (Tp15, Tp17 and Tp47) of Tp stitched
together with flexible tetra-glycyl (G4) linkers (presented with zig-zag lines). In r-Bio-Tp15-17-47, the BAP is inserted in-frame to generate the in vivo
biotinylated version of the antigen. (B) SDS-PAGE analysis of r-Tp15-17-47 and r-Bio-Tp15-17-47 antigens. Aliquots of total cell lysates of E. coli
harboring the r-p15-17-47 and r-Bio-p15-17-47 antigen constructs (uninduced: lanes marked ‘U’; induced: lanes marked ‘I’), and aliquots of the affinity-
purified dialyzed and soluble antigens (lanes marked ‘P’), were electrophoresed on denaturing gels and visualized by Coomassie staining. Protein size
markers were run in lane ‘M’; their sizes (in kDa) are shown on the left. The arrows shown denote the bands of purified proteins. The asterisk denotes
the position of biotin ligase enzyme.
doi:10.1371/journal.pone.0084050.g001
Figure 2. Design and evaluation of the in-house TRF immunoassays. (A) Schematic representation of the in-house TRF immunoassay. The
design of both the TRF immunoassays was same, except for different incubation times and tracer amounts. The numbers represent the following: (1)
microtiter well surface, (2) streptavidin, (3) r-Bio-p15-17-47, (4) serum anti-Tp IgG antibody, (5) serum anti-Tp IgM antibody, and (6) r-p15-17-47 coated
on Eu3+ chelate-doped nanoparticles. (B) Scatter plot with the S/Co values of all serum samples (n = 311) analyzed in this study, using the in-house
TRF immunoassays with 1 h (x axis) and 10 min (y axis) incubation times. Different symbols represent positive (+) or negative (-) serum samples, either
from commercial panels based on the results provided by the panel supplier, or from six different categories (#1 – #6) of the in-house samples
based on their reactivities with the reference assays as described in Table 1. Symbols for different kind of samples are as the following: PSS202 (+),
filled blue triangles; PSS202 (-), empty blue triangles; QSS701 (+), filled cyan triangles; QSS701 (-), empty cyan triangle; samples of category #1, filled
red circles; samples of category #2, filled green circles; samples of category #3, filled blue circles; samples of category #4, filled magenta circles;
sample of category #5, filled olive square; samples of category #6 (except one sample), empty red circles; and exceptional sample of category #6
which gave positive results with in-house TRF immunoassays, black star. Dashed vertical and horizontal lines represent the cutoffs (at S/Co= 1) for the
two TRF immunoassays.
doi:10.1371/journal.pone.0084050.g002
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TRF immunoassay with 1 h incubation time, and S/Co ratio of
0.9 for both the samples in TRF immunoassay with 10 min
incubation time. Only the minor differences in the S/Co ratios
that are at or very close to the borderline (S/Co= 1) in these two
samples in both the TRF immunoassays, provided the negative
results in the TRF immunoassay with 10 min incubation time.
Further data analysis revealed that all of these 4 samples had low
titers of antibodies and were weak positive samples, as indicated by
the Enzygnost and TPHA test results. Three of these 4 samples are
most likely to have antibodies due to old immunity. One of these 4
samples, which was negative with both the TRF immunoassays
was from a new-born baby. A follow-up of this sample was
available and tested in this study (one of the samples in category
#4, Table 1; sample serial #13, Table 2), and again detected as
negative with both the TRF immunoassays.
Category #3 (Table 1) consisted of 27 samples that were
detected as positive with Enzygnost, but negative with TPHA and
VDRL. These results with Enzygnost may be false positive, or may
be due to old immunity or very early infection. Ten samples of this
category were detected as positive and 17 as negative with both the
TRF immunoassays. Category #4 (Table 1) consisted of 8 samples
that produced indeterminate results with Enzygnost, and negative
results with TPHA and VDRL tests. None of these 8 samples were
detected as positive in the TRF immunoassays. Category #3 and
#4 together consisted of 35 samples from 25 persons. The results
obtained using the reference assays and the TRF immunoassays,
with these samples and three additional samples have been
described in Table 2. None of the primary samples or their follow-
ups with a negative syphilis status detected as positive in both the
TRF immunoassays, although these samples were detected as
positive in Enzygnost syphilis reference test. One sample (serial
#2) detected as negative with both the TRF immunoassays, but its
syphilis status was positive based on Inno-Lia syphilis test result
obtained with the previous sample from the same patient (data not
shown). However, a follow-up sample from this patient was not
available. One sample (serial #7) was detected as negative, but its
respective follow-up sample was detected as positive in both the
TRF immunoassays. Other samples and/or their follow-ups with
positive syphilis status were detected correctly in both the TRF
immunoassays. Two samples with unknown syphilis status were
detected as positive, and five samples with unknown syphilis status
were detected as negative in both the TRF immunoassays.
Category#5 (Table 1) consisted of a lone sample which was low
positive with Enzygnost and VDRL, and negative with TPHA test.
A follow-up sample from this person was not available to us. Both
the TRF immunoassays identified this sample as positive.
Category #6 (Table 1) consisted of 120 samples that were all
negative with Enzygnost assay. These samples were not tested
further with TPHA or VDRL reference assays. All of these
samples were identified correctly with both the TRF immunoas-
says, except for one. This lone exceptional sample was detected as
positive with both the TRF immunoassays repeatedly. This sample
was re-tested with Enzygnost, TPHA and VDRL, and detected as
negative with all three reference assays.
The performances of these TRF immunoassays were further
evaluated with two commercially available panels. Syphilis Mixed
Titer Performance Panel (PSS202) is a panel of naturally occurring
plasma samples. The panel consisted of 18 Tp positive and 2 Tp
negative samples based on the assays performed for the detection
of treponemal and non-treponemal antibodies using the commer-
cial kits, as indicated in Table 3. Both the TRF immunoassays
identified all the samples unequivocally. Syphilis qualification
panel (QSS701) consists of six samples with established reactivity
in syphilis assays. These samples were manufactured from human
serum or plasma, and five of them are reactive and one is non-
reactive in syphilis assays. Both the TRF immunoassays identified
all the samples correctly without any ambiguity (Table 4).
The sensitivity and specificity of both the TRF immunoassays
were calculated by using the samples of the in-house panel and
commercial panel that were established as either positive (samples
of category #1 and #2 of Table 1, and 18 positive samples of
PSS202) or negative (samples of category #6 of Table 1, and 2
negative samples of PSS202) for treponemal antibodies based on
the results of the commercial reference assays. The sensitivity of
TRF immunoassay with 10 min incubation time was 97.4%, and
of TRF immunoassay with 1 h incubation time was 98.7%. The
specificities of both the TRF immunoassays were 99.2%.
Data obtained in this study indicated that there is a very good
correlation in between the two TRF immunoassays. To delineate
this observation more precisely, a scatter plot was drawn to
compare the S/Co values obtained for all the samples used in this
study in both the TRF immunoassays. The coefficient of
determination (R2) of the linear regression for the two TRF
immunoassays was 0.9446 (Figure 2B). The two TRF immuno-
assays produced proximate S/Co values for most of the samples
(p = 0.06, using paired t-test). Our results indicate that the
likelihood of getting similar qualitative results with similar S/Co
ratios for the screening of treponemal antibodies in the serum/
plasma samples in the two TRF immunoassays is very high.
Discussion
The diagnosis of syphilis is primarily based on serological
immunoassays namely treponemal and non-treponemal tests
because, (i) the culture of the bacteria in vitro has not been possible
so far, (ii) the nucleic acid tests are expensive and not widely
available to all of the laboratories, (iii) and direct visualisation of
the bacteria requires sophisticated microscopy techniques, which
has its own limitations, and is not available in all of the laboratories
[21]. Syphilis diagnosis is complex, and there are different
algorithms being followed for its diagnosis, namely traditional
algorithm where the non-treponemal antibodies are first tested with
rapid plasma reagin (RPR) or VDRL and the positive results are
further confirmed with treponemal antibodies test e.g. TPHA, and
reverse algorithm in which treponemal antibodies are first tested with
an immunoassay, and positive samples are further tested with
another treponemal assay e.g. TPHA and with a non-treponemal
assay [22,23]. There are several publications where the arguments
have been given for shifting to the reverse algorithm from the
traditional one [16,22–24]. Countries like Finland are already
following the reverse algorithm, and all the in-house samples used
in this study are characterized following this algorithm only. The
dependence on serologic assays for the diagnosis of syphilis calls for
highly sensitive and specific treponemal and non-treponemal
antibodies tests.
In this study we have sought to develop a sensitive immunoassay
for the treponemal antibodies that could be used as screening test
in clinical laboratories as well as in blood-bank settings. While
developing this immunoassay two main aspects were kept in mind
namely, affordability and performance. Since Tp15, Tp17 and
Tp47 are very immunogenic proteins and show good performance
in the diagnosis of treponemal antibodies, we fused these three
antigens in tandem using flexible tetra-glycyl linkers to design the
fusion protein Tp15-17-47. We used r-Bio-Tp15-17-47 antigen as
capture and r-Tp15-17-47 antigen coated on Eu-nanoparticle as
tracer to devise double antigen sandwich or bridge TRF
immunoassays with two different incubation times of 10 min
and 1 h. Both the TRF immunoassays were evaluated with in-
Immunoassay for Treponemal Antibodies
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house and commercial serum/plasma sample panels. Samples
from in-house panel were divided into different categories (#1–
#6) (Table 1). All the samples from category#1 were positive with
the three reference assays indicating that these samples belonged
to the patients who had active or recently treated Tp infections.
Patients with active infection need urgent medical treatment in
order to avoid any complications and further transmission of
infection to others. Both the TRF immunoassays identified these
samples correctly indicating their high sensitivities to recognise
treponemal antibodies.
All the samples of category #2 were positive only with
Enzygnost and TPHA reference assays, indicating that these
samples have only the treponemal antibodies that are most likely
due to the old immunity or due to very early infection where the
levels of reagin antibodies are too low to be detected. The samples
of this category that were detected as negative with the TRF
immunoassays included a sample from a new-born baby, and a
follow-up of this sample was also detected as negative with both
the TRF immunoassays. This was likely a case of declining
maternal antibodies in the new-born, because it is established that
the maternal treponemal IgG may cross the placenta [25]. The
individuals belonging to this category are not considered to have
an active Tp infection, and are not needed to be given medical
treatment. So the samples of this category that were detected as
negative by the TRF immunoassays are not clinically relevant.
Table 3. Evaluation of the TRF immunoassays using Syphilis Mixed Titer Performance Panel (PSS202).
RPR, result expressed as Titera
ATA, result expressed as
S/Coa
ATA, result expressed as
resulta
TRF immunoassays,
result expressed as S/Cob
Member ID#
Becton-
Dickinson Wampole Diesse EIA Trinity EIA
Fujirebio
TPPA
Olympus
TPHA
10 min
incubation 1 h incubation
1 128 128 .5.5 4.4 R R 98.1 (+) 57.1 (+)
2 8 8 .5.5 3.8 R R 59.9 (+) 57.3 (+)
3 4 4 .5.5 3.3 R R 87.7 (+) 91.0 (+)
4 Neg Neg 0.3 0.3 NR NR 0.2 (2) 0.2 (2)
5 1 Neg .5.5 2.2 R R 66.7 (+) 54.7 (+)
6 64 128 .5.5 4.5 R R 108.4 (+) 71.5 (+)
7 8 8 .5.5 3.6 R R 83.0 (+) 67.5 (+)
8 1 1 .5.5 2.3 R R 32.0 (+) 26.6 (+)
9 32 32 4.5 3.8 R R 67.0 (+) 44.4 (+)
10 16 16 .5.5 4.4 R R 93.8 (+) 55.3 (+)
11 4 4 5.1 2.5 R R 25.2 (+) 26.1 (+)
12 32 64 .5.5 3.9 R R 109.3 (+) 67.0 (+)
13 1 2 .5.5 3.2 R R 108.2 (+) 93.0 (+)
14 2 2 .5.5 3.3 R R 64.4 (+) 53.1 (+)
15 32 64 .5.5 3.5 R R 75.2 (+) 45.1 (+)
16 Neg Neg 0.3 0.3 NR NR 0.4 (2) 0.3 (2)
17 2 2 .5.5 2.4 R R 61.9 (+) 59.0 (+)
18 1 Neg .5.5 2.4 R R 60.7 (+) 42.9 (+)
19 2 2 .5.5 2.2 R R 35.2 (+) 46.7 (+)
20 Neg Neg .5.5 2.2 R R 53.4 (+) 45.0 (+)
aAssays performed using commercial kits as indicated. Results were provided by the panel supplier. RPR, rapid plasma reagin; ATA, anti-Treponema antibody; S/Co,
signal to cutoff ratio; EIA, enzyme immunoassay; TPPA, Treponema pallidum particle agglutination assay; TPHA, Treponema pallidum haemagglutination assay; Neg,
negative; R, reactive; NR, non-reactive. RPR results are endpoint dilutions. S/Co ratios $1.0 are considered reactive.
bValues indicate S/Co ratios obtained in this study, using the in-house TRF immunoassays with 10 min and 1 h incubation times. Samples with S/Co values ,1.0 are
designated as negative (2) and those with values $1.0 are designated as positive (+).
doi:10.1371/journal.pone.0084050.t003
Table 4. Evaluation of the TRF immunoassays using Syphilis
Qualification Panel (QSS701).
TRF immunoassaysc
Member
ID#a
Syphilis
reactivityb
10 min
incubation 1 h incubation
1 R 125.6 (+) 88.8 (+)
2 R 81.0 (+) 88.3 (+)
3 R 83.3 (+) 91.3 (+)
4 R 49.6 (+) 68.6 (+)
5 R 93.7 (+) 69.3 (+)
6 NR 0.3 (2) 0.3 (2)
aMembers of the panel are manufactured from human serum or plasma, as
provided by the panel supplier. Five members are formulated with various
reactivities of Syphilis. Non-reactive member was formulated from Syphilis non-
reactive pools.
bResults were provided by the panel supplier. R, reactive; NR, non-reactive.
cValues indicate S/Co ratios obtained in this study, using the in-house TRF
immunoassays with 10 min and 1 h incubation times. Samples with S/Co values
,1.0 are designated as negative (2) and those with values $1.0 are designated
as positive (+).
doi:10.1371/journal.pone.0084050.t004
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Samples of Category #3 and #4 are further delineated in
Table 2. Two samples (serial #2 and #7) with positive syphilis
status were detected as negative with the TRF immunoassays. One
sample (serial #2) was given positive syphilis status based on the
result obtained from its previous sample; this is most likely a case of
resolved Tp infection. Follow-up of sample serial #7 turned
positive with both the TRF immunoassays. With this follow-up
sample TPHA test provided low positive result, indicating that
most likely this was a case of an on-going syphilis infection with
seroconverting antibodies. Data from Table 2 indicate that the
TRF immunoassays are not likely to produce any false positive
results, and are more specific than the Enzygnost syphilis EIA as
screening test for treponemal antibodies.
The results obtained for the lone sample of category #5
(Table 1) with the reference assays indicate that perhaps this was a
case of very recent primary Tp infection. One sample of category
#6 which was detected as positive (S/Co=2.5 and 3 with TRF
immunoassays with 10 min and 1 h incubation times, respectively)
with both the TRF immunoassays, might be a case of previous
immunity or an acute Tp infection which was not detected by the
three reference assays, however a follow-up of this sample was not
available to us. The TRF immunoassays were further evaluated
with the two commercial panels, and all the samples were
unequivocally identified. The overall results obtained in the TRF
immunoassays with the in-house and commercial panels indicate
that these developed assays are highly sensitive and specific for the
detection of treponemal antibodies.
Much higher S/Co values were obtained in both the TRF
immunoassays with in-house panel (data not shown) and
commercial panel (Table 3) as compared to the respective
reference EIAs used. High S/Co values obtained in the TRF
immunoassays are attributable to the design of the fusion antigen
and the strategy to amplify the signals using Eu-nanoparticles as
labels. These antigens were produced in-house using E. coli
expression system. The advantage of using fusion proteins was a
much lower production cost as compared to the production of
three different biotinylated and non-biotinylated antigens. A fusion
protein also contributes to the higher epitope density of the
capture surface, hence increasing the sensitivity of the immuno-
assay. Using a double antigen sandwich assay approach we have
devised third generation immunoassays that can by design detect
total treponemal antibodies (IgM and IgG) [26].
Both the TRF immunoassays performed in approximately the
same way in identifying the samples correctly, irrespective of the
incubation times involved in the two assays. This implies that
10 min incubation time is sufficient for the TRF immunoassay to
detect treponemal antibodies. High performance of the TRF
immunoassay coupled with a short incubation time makes it
suitable for use as a screening test not only in the clinical
laboratories where the results need to be produced as soon as
possible in order to determine the syphilis status of the patients,
but also in blood-bank settings. In-house TRF immunoassay is
capable to be automated on high-throughput instrumentations,
further making it suitable for use as a screening test in large
centralized laboratories. In future, the use of up-conversion-based
nanoparticles as reporter that can be detected using a low-cost
reader instrument will pave the way for an inexpensive test that
can be used without compromising the performance in resource
poor laboratories also.
Acknowledgments
The authors wish to thank Dr. Tytti Vuorinen from Department of
Virology, University of Turku, Turku, Finland, for providing laboratory
space to handle human serum/plasma samples. Authors also like to extend
their thanks to Ms. Puja and Ms. Shobha Kumari for their excellent
technical assistance.
Author Contributions
Conceived and designed the experiments: SMT JH NK KP. Performed the
experiments: SMT AW SK. Analyzed the data: SMT JH. Wrote the paper:
SMT JH NK KP.
References
1. World Health Organization website. Global incidence and prevalence of
selected curable sexually transmitted infections – 2008. Available: http://apps.
who.int/iris/bitstream/10665/75181/1/9789241503839_eng.pdf. Accessed
2013 Nov 22.
2. Newman L, Kamb M, Hawkes S, Gomez G, Say L, et al. (2013) Global
estimates of syphilis in pregnancy and associated adverse outcomes: analysis of
multinational antenatal surveillance data. PLoS Med 10: e1001396.
3. Ho EL, Lukehart SA (2011) Syphilis: using modern approaches to understand an
old disease. J Clin Invest 121: 4584–4592.
4. Tucker JD, Bu J, Brown LB, Yin YP, Chen XS, et al. (2010) Accelerating
worldwide syphilis screening through rapid testing: a systematic review. Lancet
Infect Dis 10: 381–386.
5. Stoner BP (2007) Current controversies in the management of adult syphilis.
Clin Infect Dis 44 Suppl 3: S130–146.
6. Kiss S, Damico FM, Young LH (2005) Ocular manifestations and treatment of
syphilis. Semin Ophthalmol 20: 161–167.
7. Schmidt PJ (2001) Syphilis, a disease of direct transfusion. Transfusion 41: 1069–
1071.
8. Kubio C, Tierney G, Quaye T, Nabilisi JW, Ziemah C, et al. (2012) Blood
transfusion practice in a rural hospital in Northern Ghana, Damongo, West
Gonja District. Transfusion 52: 2161–2166.
9. Pallavi P, Ganesh CK, Jayashree K, Manjunath GV (2011) Seroprevalence and
trends in transfusion transmitted infections among blood donors in a university
hospital blood bank: a 5 year study. Indian J Hematol Blood Transfus 27: 1–6.
10. Larsen SA, Steiner BM, Rudolph AH (1995) Laboratory diagnosis and
interpretation of tests for syphilis. Clin Microbiol Rev 8: 1–21.
11. World Health Organization website. Screening donated blood for transfusion-
transmissible infections: recommendations. Available: http://www.who.int/
bloodsafety/ScreeningDonatedBloodforTransfusion.pdf. Accessed 2013 Nov 22.
12. Sun AH, Mao YF, Hu Y, Sun Q, Yan J (2009) Sensitive and specific ELISA
coated by TpN15-TpN17-TpN47 fusion protein for detection of antibodies to
Treponema pallidum. Clin Chem Lab Med 47: 321–326.
13. Baughn RE, Demecs M, Taber LH, Musher DM (1996) Epitope mapping of B-
cell determinants on the 15-kilodalton lipoprotein of Treponema pallidum
(Tpp15) with synthetic peptides. Infect Immun 64: 2457–2466.
14. Baughn RE, Jiang A, Abraham R, Ottmers V, Musher DM (1996) Molecular
mimicry between an immunodominant amino acid motif on the 47-kDa
lipoprotein of Treponema pallidum (Tpp47) and multiple repeats of analogous
sequences in fibronectin. J Immunol 157: 720–731.
15. Norris SJ (1993) Polypeptides of Treponema pallidum: progress toward
understanding their structural, functional, and immunologic roles. Treponema
Pallidum Polypeptide Research Group. Microbiol Rev 57: 750–779.
16. Sena AC, White BL, Sparling PF (2010) Novel Treponema pallidum serologic
tests: a paradigm shift in syphilis screening for the 21st century. Clin Infect Dis
51: 700–708.
17. Batra G, Talha SM, Nemani SK, Dhar N, Swaminathan S, et al. (2010)
purification and characterization of in vivo biotinylated dengue virus envelope
domain III based tetravalent antigen. Prot Expr Purif 74: 99–105.
18. Talha SM, Salminen T, Swaminathan S, Soukka T, Pettersson K, et al. (2011) A
highly sensitive and specific time resolved fluorometric bridge assay for
antibodies to HIV-1 and -2. J Virol Methods 173: 24–30.
19. Ha¨rma¨ H, Soukka T, Lo¨vgren T (2001) Europium nanoparticles and time-
resolved fluorescence for ultrasensitive detection of prostate specific antigen. Clin
Chem 47: 561–568.
20. Soukka T, Ha¨rma¨ H, Paukkunen J, Lo¨vgren T (2001) Utilization of kinetically
enhanced monovalent binding affinity by immunoassays based on multivalent
nanoparticle-antibody bioconjugates. Anal Chem 73: 2254–2260.
21. Clyne B, Jerrard DA (2000) Syphilis testing. The Journal of Emergency
Medicine 18: 361–367.
22. Binnicker MJ, Jespersen DJ, Rollins LO (2012) Direct comparison of the
traditional and reverse syphilis screening algorithms in a population with a low
prevalence of syphilis. J Clin Microbiol 50: 148–150.
23. Loeffelholz MJ, Binnicker MJ (2012) It is time to use treponema-specific
antibody screening tests for diagnosis of syphilis. J Clin Microbiol 50: 2–6.
Immunoassay for Treponemal Antibodies
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e84050
24. Marangoni A, Moroni A, Accardo S, Cevenini R (2009) Laboratory diagnosis of
syphilis with automated immunoassays. J Clin Lab Anal 23: 1–6.
25. Herremans T, Kortbeek L, Notermans DW (2010) A review of diagnostic tests
for congenital syphilis in newborns. Eur J Clin Microbiol Infect Dis 29: 495–501.
26. Rostopira N, Tkacikova L, Rayevska G, Pylypenko V, Mikula I, et al. (2003)
Elaboration of enzyme immunoassay based on recombinant antigens and
intended for diagnostics of syphilis. Folia Microbiol (Praha) 48: 549–553.
Immunoassay for Treponemal Antibodies
PLOS ONE | www.plosone.org 9 December 2013 | Volume 8 | Issue 12 | e84050
